Champions Oncology (CSBR) Tax Provisions (2011 - 2026)
Champions Oncology (CSBR) posted quarterly Tax Provisions of $172000.0 for Q2 2026, up 233.33% year-over-year from $51600.0 in Q2 2025, and up 309.52% quarter-over-quarter from $42000.0 in Q1 2026.
Champions Oncology (CSBR) Tax Provisions (2011 - 2026) Analysis & Trends
Champions Oncology's Tax Provisions history runs 16 years deep, the most recent figure standing at $172000.0 for Q2 2026.
- In Q2 2026, Tax Provisions rose 233.33% year-over-year to $172000.0; the TTM figure through Apr 2026 stood at $246000.0 (up 432.43% YoY), while the FY2026 annual figure was $246000.0, up 428.0% from the prior year.
- Tax Provisions for Q2 2026 stood at $172000.0, up from $42000.0 in the prior quarter.
- The five-year high for Tax Provisions was $172000.0 in Q2 2026, with the low at -$129000.0 in Q2 2025.
- The 5-year median for Tax Provisions is $15500.0 (2022), against an average of $12111.1.
- The sharpest annual moves came in 2023 and 2024: Tax Provisions surged 1100.0% in 2023, then slumped 505.0% in 2024.
- Champions Oncology's Tax Provisions stood at $14000.0 in 2022, then slipped by 21.43% to $11000.0 in 2023, then changed by 0.0% to $11000.0 in 2024, then jumped by 63.64% to $18000.0 in 2025, then jumped by 855.56% to $172000.0 in 2026.
- Business Quant data shows CSBR's Tax Provisions at $172000.0 in Q2 2026, $42000.0 in Q1 2026, and $18000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 59.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 15.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 75.45 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 13.31 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.90 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -90.33 Mn |
| 10 | Champions Oncology | 71.17 Mn | 71.17 Mn | 7.03 Mn | 172,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 172,000.00 |
| Jan 31, 2026 | 42,000.00 |
| Oct 31, 2025 | 18,000.00 |
| Jul 31, 2025 | 14,000.00 |
| Apr 30, 2025 | -129,000.00 |
| Jan 31, 2025 | 23,000.00 |
| Oct 31, 2024 | 11,000.00 |
| Jul 31, 2024 | 21,000.00 |
| Apr 30, 2024 | -81,000.00 |
| Jan 31, 2024 | 11,000.00 |
| Oct 31, 2023 | 11,000.00 |
| Jul 31, 2023 | 28,000.00 |
| Apr 30, 2023 | 20,000.00 |
| Jan 31, 2023 | 17,000.00 |
| Oct 31, 2022 | 14,000.00 |
| Jul 31, 2022 | 17,000.00 |
| Apr 30, 2022 | -2,000.00 |
| Jan 31, 2022 | 11,000.00 |
| Oct 31, 2021 | 12,000.00 |
| Jul 31, 2021 | 14,000.00 |